Dermatologists are practicing in an “era of good efficacy” of nonsteroidal topical therapies for psoriasis, and they can help patients access newer topical medications by working with pharmacies that ...

The main growth driver for Alkermes going forward will be ALKS 2680. Read why I maintain my buy rating on ALKS stock.

Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has dosed the first patient in the phase 2a part of the GOAL-HF1 clinical study. The study will ...

The case, filed in the U.S. District Court for the District of New Jersey under the title Moon v. Novo Nordisk A/S, No. 25-cv-00713, alleges that the company and its key executives committed ...

The global Metastatic Cancer Drugs market was valued at US$ 72.64 billion in 2023 and is projected to reach US$ 136.95 billion by 2032, growing at a CAGR of 26.3% from 2024 to 2032. Read the Market ...

If you’ve been wanting to add a retinol into your skin care routine but don’t know where to start, we tapped a few experts ...

The FDA has approved label changes for once-monthly Sublocade, helping to reduce possible barriers to treatment initiation ...

Ensho Therapeutics has presented additional data supporting NSHO-101, also referred to as EA1080, as an oral one-time-a-day ...

Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies ...

A PDUFA date has been set for October 20, 2025. If approved, Epoxia will be the first epi-on corneal crosslinking on the market.

Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...